[
  {
    "ts": "2025-12-20T02:31:18+00:00",
    "headline": "After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss",
    "summary": "The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance. Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAI",
    "url": "https://finance.yahoo.com/news/wegovy-zepbound-shots-eli-lilly-023118660.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "d73cc276-5948-363c-aea9-af30804f350c",
      "content": {
        "id": "d73cc276-5948-363c-aea9-af30804f350c",
        "contentType": "STORY",
        "title": "After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss",
        "description": "",
        "summary": "The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance. Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAI",
        "pubDate": "2025-12-20T02:31:18Z",
        "displayTime": "2025-12-20T02:31:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/8130383f2711756678a6ced7cac56500",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BYuMwmI3x3VhS2__3kh_RQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/8130383f2711756678a6ced7cac56500.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/blMiVLO204sA.faQLuSy.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/8130383f2711756678a6ced7cac56500.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wegovy-zepbound-shots-eli-lilly-023118660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wegovy-zepbound-shots-eli-lilly-023118660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]